ACP
NMTR

Arcus Capital Partners’s 9 Meters Biopharma NMTR Stock Holding History

Arcus Capital Partners’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-81
Closed -$10K – 127
2017
Q4 		$10K Buy
+81
New +$10.4K 0.01% 112

Other funds holding NMTR

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
DWM
Dynasty Wealth Management St. Petersburg, Florida $11.5B AUM 15.23% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Arcus Capital Partners's NMTR Position: Q1 2018 in Review

Arcus Capital Partners sold out of 9 Meters Biopharma (NMTR) in Q1 2018, closing a stake of 81 shares — an estimated $10K sold.

Arcus Capital Partners first reported a position in NMTR in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 15 funds tracked by Wall St. Rank hold NMTR as of Q1 2018.

  • Arcus Capital Partners reported no remaining 9 Meters Biopharma position as of Q1 2018 after selling out during the quarter.
  • Arcus Capital Partners sold 81 9 Meters Biopharma shares in Q1 2018, an estimated $10K.
  • Arcus Capital Partners first reported a position in 9 Meters Biopharma in Q4 2017 and held it in 1 quarter.
  • Arcus Capital Partners's 9 Meters Biopharma position peaked at $10K in Q4 2017.
  • 15 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2018.

Based on Arcus Capital Partners's 13F filing for Q1 2018, filed 14 May 2018.